No Data
No Data
No Data
No Data
No Data
LEFTFIELD PRINT To Go Ex-Dividend On May 21st, 2024 With 0.04 HKD Dividend Per Share
March 28th - $LEFTFIELD PRINT(01540.HK)$ is trading ex-dividend on May 21st, 2024. Shareholders of record on May 22nd, 2024 will receive 0.04 HKD dividend per share on June 12th, 2024. The ex-divi
moomoo NewsMar 28 05:10 ET
Australian Lion Global (01540.HK): Net profit of HK$333.33 million increased 197% year-on-year in 2023
Glonghui, March 27, 丨 Australian Lion Global (01540.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$558 million, up 10.4% year on year; profit attributable to company owners was about HK$33,333 million, up 197% year on year; basic profit per share was 6.68 HK cents, with a proposed final dividend of HK4 cents per share.
Gelonghui FinanceMar 27 08:06 ET
Australian Lion Global (01540) will pay a final dividend of HK$0.04 per share on June 12
According to the Zhitong Finance App, Australian Lion Global (01540) announced that the company will pay a final dividend of HK$0.04 per share for the year ended December 31, 2023 on June 12, 2024.
Zhitong FinanceMar 27 08:00 ET
LEFTFIELD PRINT: RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Futu NewsMar 27 07:56 ET · Announcements
Australian Lion Global (01540.HK) plans to hold a board meeting on March 27 to consider and approve annual results
Glonghui, March 15, 丨 Australian Lion Global (01540.HK) announced that the company will hold a board meeting at 3:30 p.m. on March 27, 2024 (Wednesday) at 11/F, East Wing, Green View Building, 123 Kwun Tong, Kowloon, Hong Kong. At the meeting, the board of directors will include approving the annual results of the Company and its subsidiaries for the year ended 31 December 2023 and considering the proposed payment of a final dividend (if applicable).
Gelonghui FinanceMar 15 05:20 ET
Selected Announcements | New Oriental and Yu Minhong promised to purchase a total of HK$700 million Dongfang Selected Shares; Yao Ming Joint Inc. expects adjusted net profit to increase by more than 100% last year
Saisheng Pharmaceutical: The Phase III clinical trial of Vaborem® in China completed the enrollment of all subjects; Xianruida Healthcare: The registration application for PERIDGE® was approved by the China National Drug Administration.
Gelonghui FinanceJan 31 19:27 ET
No Data
No Data